ArticleBMC endocrine disorders2025
Elabela increases in patients with primary hyperparathyroidism, especially in the presence of surgery indication.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPatients with primary hyperparathyroidism (PHPT) are known to have structural and functional changes in the vascular system. Bioactive peptides associated with the apelinergic system play a role in ischemic heart disease and atherosclerosis. In this study, we aimed to investigate the changes in serum elabela, a novel apelinergic system peptide, and its relationship with aortic intima media (AIM) measurements in patients with newly diagnosed primary hyperparathyroidism. MATERIALS AND
methodsThe study was prospectively conducted with 45 patients with newly diagnosed Primary Hyperparathyroidism who were admitted to the Internal Medicine outpatient clinics of Adana City Training and Research Hospital. Forty people with similar demographic characteristics were included as a healthy control group. Hemogram, biochemistry, parathormone, vitamin D, urinary calcium, dual x-ray absorptiometry (DEXA), Elabela and aortic intima media levels were measured. The study groups were divided into three groups: healthy control group (Group 1: 40 patients), PHPT group without surgical indication (Group 2: 20 patients) and PHPT group with surgical indication (Group 3: 25 patients).
resultsElabela level was found to increase from group 1 to group 3. It was 2.1 (1.3–2.4) ng/mL in group 1, 10.45 (3.7-14.15) ng/mL in group 2 and 12.6 (12.0–14.0) ng/mL in group 3 (p < 0.001). AIM level was found to be statistically significantly higher in group 3 compared to groups 1 and 2. It was 1.2 (1.0-1.4) mm in group 1, 1.3 (1.2–1.6) mm in group 2 and 2.15 (1.95–2.32) mm in group 3 (p < 0.001). Linear regression analysis performed with the parameters significantly correlated with Elabela in group 3 showed that DEXA and AIM levels were independently associated with Elabela. In the multivariate logistic regression analysis performed for the independent determination of patients with surgical indication in the patient group, it was found that Elabela level independently determined the group with surgical indication. According to this analysis, each 1 unit increase in Elabela level increased the probability of surgery by 30.9% in the patient group.
conclusionIn patients with primary hyperparathyroidism, serum Elabela level may be increased due to activation of the Apelinergic system in response to adverse vascular and cardiac effects that may be caused by increased parathormone. Elabela level can be used to determine the indication for surgery in PHPT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.